A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019

A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019

Background: COVID-2019 pandemic lead to a raised interest on the development of new treatments through Artificial Intelligence (AI). Aim: to carry out a systematic review on the development of repurposed drugs against COVID-2019 through the application of AI. Methods: The Systematic Reviews and Meta...

Full description

Bibliographic Details
Main Author:	Carla Pires
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Journal of Personalized Medicine
Subjects:	artificial intelligence COVID-2019 SARS-CoV-2 drug design medicines repurposing of drugs
Online Access:	https://www.mdpi.com/2075-4426/11/9/926

Similar Items

Artificial intelligence approach fighting COVID-19 with repurposing drugs
by: Yi-Yu Ke, et al.
Published: (2020-08-01)

A review of SARS-CoV-2 drug repurposing: databases and machine learning models
by: Marim Elkashlan, et al.
Published: (2023-08-01)

Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
by: Atsushi Hijikata, et al.
Published: (2022-01-01)

Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets
by: Luis C. Vesga, et al.
Published: (2022-04-01)

Strategies for drug repurposing against coronavirus targets
by: Poppy O. Smith, et al.
Published: (2022-01-01)

Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model
by: Yun-Ti Chen, et al.
Published: (2022-12-01)

Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors
by: Selvaa Kumar Chellasamy, et al.
Published: (2022-10-01)

Editorial: Artificial intelligence and machine learning for drug discovery, design and repurposing: methods and applications
by: Pan Zheng, et al.
Published: (2023-11-01)

Artificial intelligence is being utilized to drive drug repurposing as a new strategy for managing asthmatic attacks
by: Hinpetch Daungsupawong, et al.
Published: (2023-01-01)

Evaluating the effect of artificial intelligence on pharmaceutical product and drug discovery in China
by: Agyemang Kwasi Sampene, et al.
Published: (2024-04-01)

In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants
by: Calvin R. Wei, et al.
Published: (2024-01-01)

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
by: Liliana Rodrigues, et al.
Published: (2022-04-01)

The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2
by: Javed Akhter, et al.
Published: (2021-03-01)

Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach
by: Tamizhini Loganathan, et al.
Published: (2020-06-01)

In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment
by: Jesse W. Wotring, et al.
Published: (2022-08-01)

Integration of Omics Data and Network Models to Unveil Negative Aspects of SARS-CoV-2, from Pathogenic Mechanisms to Drug Repurposing
by: Letizia Bernardo, et al.
Published: (2023-08-01)

Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant
by: Nirmitee Mulgaonkar, et al.
Published: (2023-07-01)

Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19
by: Hoda Awad, et al.
Published: (2022-08-01)

FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
by: Mahmoud S. Ahmed, et al.
Published: (2023-06-01)

Valinomycin as a potential antiviral agent against coronaviruses: A review
by: Dong Zhang, et al.
Published: (2020-10-01)

Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19
by: Gunjan Arora, et al.
Published: (2021-08-01)

COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
by: Mario Roberto Senger, et al.

β-Cyclodextrins as affordable antivirals to treat coronavirus infection
by: Dalia Raïch-Regué, et al.
Published: (2023-08-01)

Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus
by: Olivier Terrier, et al.
Published: (2021-04-01)

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
by: Sunny Kumar, et al.
Published: (2023-07-01)

Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery
by: Anita Ioana Visan, et al.
Published: (2024-02-01)

Unravelling Insights into the Evolution and Management of SARS-CoV-2
by: Aganze Gloire-Aimé Mushebenge, et al.
Published: (2024-02-01)

Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection
by: Özge Osmanoglu, et al.
Published: (2023-12-01)

Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey
by: Estefanía Calvo-Alvarez, et al.
Published: (2022-06-01)

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
by: Dan-Yang Liu, et al.
Published: (2021-04-01)

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
by: Ahmed Mostafa, et al.
Published: (2020-12-01)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
by: Tonino Alonzi, et al.
Published: (2021-12-01)

In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage
by: E. Sila Ozdemir, et al.
Published: (2022-05-01)

Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
by: Pawan Kumar Raghav, et al.
Published: (2023-05-01)

Corrigendum: Editorial: The mechanisms of action of anti-SARS-CoV-2 drugs
by: Wu Zhong, et al.
Published: (2022-11-01)

Editorial: The Mechanisms of Action of Anti-SARS-CoV-2 Drugs
by: Wu Zhong, et al.
Published: (2022-04-01)

Design of SARS-CoV-2 Main Protease Inhibitors Using Artificial Intelligence and Molecular Dynamic Simulations
by: Lars Elend, et al.
Published: (2022-06-01)

Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model
by: Yoonjung Choi, et al.
Published: (2020-11-01)

Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
by: Wael Hafez, et al.
Published: (2022-04-01)

Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients
by: Federico Romano, et al.
Published: (2021-08-01)